Challenges in the Treatment of Hepatorenal Syndrome-Acute Kidney Injury: A US Chart Review of Treatment Patterns and Survival Outcomes.

ABSTRACT:

Background

Treatments for hepatorenal syndrome with acute kidney injury (HRS-AKI) that are not FDA-approved have been widely used in the United States (US) with variable outcomes. This study describes the practice patterns, outcomes, and healthcare utilization around vasopressor use before terlipressin approval in 2022.

Methods

A retrospective chart review study was conducted at 10 US medical centers, assessing adult patients diagnosed with HRS-AKI between 2016 and 2019. The primary outcome was treatment response (change in serum creatinine [SCr] from the day of vasopressor treatment initiation to Day 14/vasopressor discontinuation). Secondary outcomes included overall and transplant-free survival, treatment patterns, and healthcare resource use.

Results

Of the 198 el

SUBMITTER: Sanyal AJ 

PROVIDER: S-EPMC12434070 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature